Scinai Immunotherapeutics
SCNI
7 hedge funds and large institutions have $2.34M invested in Scinai Immunotherapeutics in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.12% less ownership
Funds ownership: 2.31% → 2.2% (-0.12%)
30% less funds holding
Funds holding: 10 → 7 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $64K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Psagot Value Holdings
Tel Aviv,
Israel
|
-$59K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5K |
SCNI Hedge Fund Activity: Q2 2019 in Review
7 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2019, worth a combined $2.34M — up 3.1% from $2.27M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Psagot Value Holdings, exiting entirely with an estimated $59K sold.
- 7 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2019, down from 10 in Q1 2019.
- Funds reported $2.34M of Scinai Immunotherapeutics stock for Q2 2019, up 3.1% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q2 2019 and 3 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics seller in Q2 2019 was Psagot Value Holdings, an estimated $59K sold.
Based on aggregated 13F filings for Q2 2019.